RNAi Technology Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.36 Billion |
| Market Size (2029) | USD 2.90 Billion |
| CAGR (2024 - 2029) | 16.29 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
RNAi Technology Market Analysis
The Global RNA-interference Market size is estimated at USD 1.36 billion in 2024, and is expected to reach USD 2.9 billion by 2029, growing at a CAGR of 16.29% during the forecast period (2024-2029).
COVID-19 is expected to have a significant impact on the growth of the market. The demand for RNA interference is expected to increase as it is effectively used for the development of COVID-19 disease therapeutics. According to the article titled 'Prospects for RNAi therapy of COVID-19' published in July 2020, RNAi against COVID-19 disease can potentially be directed against two different categories of targets such as viral proteins essential in survival and replication of SARS-CoV-2 and Host factors involved in cellular entry and trafficking of the virus. Such potential benefits of RNA interference for the development of COVID-19 therapy is expected to drive the growth of the market.
Certain factors that are driving the market growth include the increasing number of applications in molecular diagnostics, particularly in cancer, and improving synthetic delivery carriers and chemical modifications to RNA.
Cancer diagnosis and treatment are currently undergoing a shift with the incorporation of RNAi techniques in personalized medicine and molecular diagnostics. The availability of high throughput techniques for the identification of altered cellular molecules and metabolites allows the use of RNAi techniques in various cancer diagnosis and targeting approaches. According to the article titled ' Insight into the prospects for RNAi Therapy of Cancer' published in March 2021 the expression of terget genes is knocked by RNAi, locating these nodes which are insipensable to tumor maintenance, with low side effects and low risk, blocking the inherent immunosuppression and triggering immune attacks on tumors. Moreover one of the advantages of RNAi technology is the rapid development of efficacious and targeted drugs for controlling tumor growth. For diagnostic purposes, small interfering RNAs (siRNA) or microRNAs (miRNA) can be utilized. The commercial availability of siRNAs to silence virtually any gene in the human genome is dramatically accelerating the pace of molecular diagnosis and biomedical research. For instance in December 2020 expanded its existing cooperation scope, including the development and commercialization of RNAi therapeutic drugs. the company used its latest progress in targeted delivery of siRNA drugs and its established capabilities to deepen the development of RNAi drugs for tumors and neurological diseases. Thus, increasing the application of RNAi in molecular diagnosis and its viability as a therapeutic technique may boost the growth of the RNAi market.
Thus the above mentioned factors are expected to fuel the growth of the market during the forecast period.
RNAi Technology Market Trends
This section covers the major market trends shaping the RNA-interference (RNAi) Market according to our research experts:
Oncology is Expected to Hold Significant Market Share in the Therapeutics Type
The oncology segment is expected to hold a significant market share during the forecast period.
The increasing incidence of cancer among the global population leading to the rise in demand for effective therapeutics is expected to drive the growth of the studied segment. As per the report of the International Agency for Research on Cancer published GLOBOCAN 2020 report, there were an estimated 19,292,789 new cases of cancer diagnosed in 2020 and about 9,958,133 people died due to cancer, all over the world. As per the same source, of the total diagnosed cancer cases, 10,065,305 cases were reported in males and 9,227,484 cases were reported in females. the incidence of cancer cases in males was expected to reach 15,585,096 by 2040 and 13,302,846 in females by 2040. Such an increasing incidence of cancer among the global population is expected to drive the growth of the market.
Recent advancements, such as the development of small interfering RNA (siRNA) tolerant to nucleases and the development of non-viral vectors, such as cationic liposomes and nanoparticles, can overcome this obstacle and facilitate the clinical use of RNAi-based therapeutics in the treatment of cancer. Substantial pipeline for cancer therapies by companies and institutes such as Enzon Pharmaceuticals (Santaris Pharma), University of Texas, OncoGenex, Isarna Therapeutics, Astrazeneca (Ionis Pharmaceuticals), and INSYS Therapeutics, Inc. are expected to drive the market. For instance, In December 2021, Novartis received United States Food and Drug Administration approval for Leqvio, the small interfering RNA (siRNA) therapy for low-density lipoprotein with two doses a year, after an initial dose and one at three months. In addition, many companies have invested in R&D for nanocarriers to deliver oligonucleotides for cancer treatment, which is expected to contribute to the oncology verticle.
Thus the above mentioned factors are expected to drive the growth of the studied segment during the forecast period.
North America Dominates the Market and Expected to do the Same in the Forecast Period
North America is expected to provide lucrative opportunities for the growth of the market owing to the rising incidence of target diseases and growing demand for advanced therapeutics and diagnostics. For instance, according to the American Cancer Society's report in 2022 over 1.9 million new cancer cases are expected to be diagnosed in the United States 2022. and additionally, 80% of the people diagnosed with cancer in the United States are 55 years of age or older and 57% are 65 or older Thus, due to the high prevalence of cancer, and the rising affected geriatric population, the demand for diagnostics and treatment is also high in the country which is expected to drive the growth in the studied market in the United States.
The United States has a number of RNAi therapeutics that are in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. key pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected growth in revenue that this market can have over the forecast period. For instance, in Dember 2021, AstraZeneca's agreement with Ionis pharmaceuticals is one of the big deals that are investing heavily into RNA-interference technology. The increasing approvals for the RNAi therapy is expected to drive the growth of the market during the forecast period. For instance in December 2021 , Novartis received United States Food and Drug Administration approval for Leqvio, the first and only small interfering RNA (SiRNA) therapy to low- density lipoprotein with two doses a year, after an initial dose and one at three months.
Thus the above mentioned factors are expected to drive the growth of the market in the studied region.
RNAi Technology Industry Overview
The RNA-interference (RNAi) market is highly competitive and consists of a few major players. Companies like Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals (Novo Nordisk A/S), Thermofisher Scientific, Silence Therapeutics PLC, among others, hold a substantial market share in the RNA-interference (RNAi) market.
RNAi Technology Market Leaders
-
Alnylam Pharmaceuticals
-
Silence Therapeutics PLC
-
Arrowhead Pharmaceuticals, Inc.
-
Thermo Fisher Scientific Inc
-
Dicerna Pharmaceuticals (Novo Nordisk A/S)
*Disclaimer: Major Players sorted in no particular order
RNAi Technology Market News
- In February 2022 Sirnaomics Lts launched the start of a Phase one clinical trial for evaluation f the safety, tolerability, and anti-tumor activity of the company's SiRNA (Small interfering RNA) drug candidate, STP707 with intravenous (IV) administration in the United States.
- In December 2021, Novartis received United States Food and Drug Administration approval for Leqvio, the small interfering RNA (siRNA) therapy for low-density lipoprotein with two doses a year, after an initial dose and one at three months.
RNAi Technology Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Number of Applications in Molecular Diagnostics, Particularly in Cancer
- 4.2.2 Improving Synthetic Delivery Carriers and Chemical Modifications to RNA
-
4.3 Market Restraints
- 4.3.1 Stringent Regulations and Changing Reimbursement Environment
- 4.3.2 Unstable Potentially Immunogenic Nature of RNA
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
5.1 By Application
- 5.1.1 Drug Discovery and Development
- 5.1.2 Therapeutics
- 5.1.2.1 Oncology
- 5.1.2.2 Ocular Disorders
- 5.1.2.3 Respiratory Disorders
- 5.1.2.4 Hepatitis B and C
- 5.1.2.5 Autoimmune Hepatitis
- 5.1.2.6 Neurological Disorders
- 5.1.2.7 Other Therapeutics
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Mexico
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 United Kingdom
- 5.2.2.3 France
- 5.2.2.4 Italy
- 5.2.2.5 Spain
- 5.2.2.6 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Rest of the World
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Alnylam Pharmaceuticals
- 6.1.2 Arcturus Therapeutics
- 6.1.3 Arrowhead Pharmaceuticals, Inc.
- 6.1.4 Dicerna Pharmaceuticals (Novo Nordisk A/S)
- 6.1.5 Ionis Pharmaceuticals Inc.
- 6.1.6 Merck & Co. Inc. (Sigma Aldrich)
- 6.1.7 Silence Therapeutics PLC
- 6.1.8 Qiagen NV
- 6.1.9 Phio Pharmaceuticals Corp.
- 6.1.10 Thermo Fisher Scientific Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
RNAi Technology Industry Segmentation
RNA interference is a biological process in which the RNA molecules are observed to inhibit gene expression or translation, by neutralizing the targeted mRNA molecules. Earlier, RNAi was identified by other names, such as co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The extensive study of each of these apparently different processes clarified that the identity of these phenomena was all in fact RNAi. The RNA-interference (RNAi) market is segmented by Application (Drug Discovery and Development, Therapeutics [Oncology, Ocular Disorders, Respiratory Disorders, Hepatitis B and C, Autoimmune Hepatitis, Neurological Disorders, and Other Therapeutics]) and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Application | Drug Discovery and Development | |
| Therapeutics | Oncology | |
| Ocular Disorders | ||
| Respiratory Disorders | ||
| Hepatitis B and C | ||
| Autoimmune Hepatitis | ||
| Neurological Disorders | ||
| Other Therapeutics | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Rest of the World |
RNAi Technology Market Research FAQs
How big is the Global RNA-interference (RNAi) Market?
The Global RNA-interference (RNAi) Market size is expected to reach USD 1.36 billion in 2024 and grow at a CAGR of 16.29% to reach USD 2.90 billion by 2029.
What is the current Global RNA-interference (RNAi) Market size?
In 2024, the Global RNA-interference (RNAi) Market size is expected to reach USD 1.36 billion.
Who are the key players in Global RNA-interference (RNAi) Market?
Alnylam Pharmaceuticals, Silence Therapeutics PLC, Arrowhead Pharmaceuticals, Inc., Thermo Fisher Scientific Inc and Dicerna Pharmaceuticals (Novo Nordisk A/S) are the major companies operating in the Global RNA-interference (RNAi) Market.
Which is the fastest growing region in Global RNA-interference (RNAi) Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global RNA-interference (RNAi) Market?
In 2024, the North America accounts for the largest market share in Global RNA-interference (RNAi) Market.
What years does this Global RNA-interference (RNAi) Market cover, and what was the market size in 2023?
In 2023, the Global RNA-interference (RNAi) Market size was estimated at USD 1.17 billion. The report covers the Global RNA-interference (RNAi) Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global RNA-interference (RNAi) Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
RNAi Technology Industry Report
Statistics for the 2024 RNAi Technology market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. RNAi Technology analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
